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Accepted 11 November 2010AbstractObjective: Preimplantation genetic diagnosis (PGD) offers an alternative for women to carry an unaffected fetus risk of hereditary diseases.
Trophectoderm biopsy may provide more cells for accurate diagnosis. However, the time allowed for transportation of the specimens to the
laboratory and performance of molecular diagnosis is limited. We designed a PGD program of trophectoderm biopsy, vitrification of blastocysts,
whole genome amplification (WGA), double confirmatory genotypings, and thawed embryo transfer.
Case Report: We conducted this strategy for a woman of familial neurofibromatosis type I (NF-1). She had a genotype of heterozygous c.6709C>T
mutation of NF1 gene. Trophectoderm biopsies were performed on 13 blastocysts. Then, individual blastocyst was vitrified. WGAwas performed
for the samples, followed by genotypings with both real-time polymerase chain reaction and sequencing. Eight embryos were diagnosed as
unaffected, four were affected, and one was inconclusive because of allele drop-out. In the next cycle, two unaffected blastocysts were thawed and
transferred, that resulted in a singleton pregnancy. The pregnancy was confirmed as unaffected by means of chorionic villi sampling.
Conclusion: We first demonstrate successful application of blastocyst biopsy, vitrification, WGA, and thawed embryo transfer for PGD of
a monogenic disease. Vitrification of blastocysts after biopsy permits sufficient time for shipment of samples and operation of molecular
diagnosis.
Copyright  2011, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Neurofibromatosis type 1 (NF-1), also known as Von
Recklinghausen disease, is an autosomal dominant disorder
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doi:10.1016/j.tjog.2011.01.040located on chromosome 17q11.2 and comprises 60 known
exons. NF1 gene encodes a protein, called neurofibromin.
NF-1 is a neurocutaneous disorder with symptoms of multiple
cafe´-au-lait spots, cutaneous neurofibromas, optic gliomas,
and iris nodules. The neurofibromas may transform into
malignant tumors in 10e20%. More than 500 different NF1
mutations have been found. In addition to conventional
prenatal diagnosis, preimplantation genetic diagnosis (PGD)
may provide an alternative to carry an unaffected fetus [1,3].
There are three potential sources of embryonic genetic
material for PGD, including polar bodies from oocytes, blas-
tomeres from cleavage-stage embryos, and trophectodermcs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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of one blastomere is the most common approach for PGD [4].
The innate dilemma of polar body or blastomere biopsy is the
limited genetic material available for analysis with risks of
amplification failure and allele drop-out (ADO). Some
misdiagnoses of PGD had been reported in the literature [4].
The biopsy of multiple trophoblast cells from blastocysts
should theoretically lead to improving sensitivity and accuracy
of PGD. Pregnancies after blastocyst biopsy for PGD have
recently been reported and merit further investigation [5,6].
Polymorphic short tandem repeat (STR) markers close to
mutated gene have been used for linkage analysis to provide
an additional confirmation of genotyping and an evidence of
ADO [7,8]. STR markers also help to detect contamination of
exogenous DNA with different STR sizes. To detect mutated
gene and STR markers, multiplex polymerase chain reaction
(PCR) is commonly used for PGD [7,8]. It is critical to design
compatible multiple primer sequences and conditions because
several PCR reactions may interfere mutually in a tube. In
addition, the procedures of multiplex PCR cannot be repeated
when one of the PCR reactions failed. In contrast, the use of
whole genome amplification (WGA) in PGD may provide
sufficient DNA templates for independent PCR reactions and
repeated confirmations [9]. The WGA for PGD of NF1 gene
and linked STR markers deserves further study.
Embryo biopsy and fresh embryo transfer are traditionally
performed in the PGD cycle. However, before embryo transfer,
the time allowed for transportation of the specimens to the
reference laboratory and conduct of molecular diagnosis is
limited, especially after blastocyst biopsy. Vitrification of blas-
tocysts has been verified to achieve high-survival rate and preg-
nancy rate [10].Accordingly,weestablish the strategyofPGDfor
monogenic diseases using blastocyst biopsy, vitrification, WGA
accompanied by double confirmatory genotypings, and thawed
embryo transfer. Using this strategy, we achieve a successful
unaffected pregnancy for a couple risk of carrying an NF-1 fetus.
Materials and methodsPatientsThe couple, a 38-year-old male and a 32-year-old female,
had a history of artificial abortion for an affected fetus of NF-
1. The wife has NF-1 disease with a genotype of heterozygous
c.6709C>T mutation of NF1 gene. Her father and grand-
mother were also affected by this disease. They hoped to have
an unaffected child.PGD counselingAn experienced geneticist and a gynecologist provided
comprehensive counseling to the couple. PGD is an alternative
method for conventional prenatal diagnosis. The procedures of
PGD, cryopreservation of the biopsied blastocysts, survival of
thawed embryos, and pregnancy potential were explained. The
odds of a misdiagnosis inherent to PGD and subsequent
genotype confirmation of the pregnancy using chorionic villisampling were discussed. This study was approved by the
Ethic Committee of National Taiwan University Hospital.
Informed consent was obtained from the couple.Testing on single lymphocytesTo evaluate the reliability of the protocol of molecular
diagnosis before the PGD cycle, the WGA, mutation analysis
with real-time PCR, and STR detections were tested on single
lymphocytes collected from the wife. Blank controls were also
processed under the same conditions to check for the presence
of contamination. The amplification efficiency, ADO rate, and
contamination rate were measured.WGAThe multiple displacement amplification (MDA) method
using GenomiPhi V2 DNA amplification kit (GE Healthcare,
Piscataway, NJ, USA) was performed for WGA, according to
the manufacturer’s instruction.Informative linked STR markerThe STR marker, close to the NF1 gene, was examined to
avoid a possible misdiagnosis resulting from ADO. An
informative intragenic STR marker of D17S1166 was used,
which showed polymorphisms of 195, 218 bp for the husband
and 193, 204 bp for the wife. The primers were 50-CCC ATA
CCT AGT TCT TAA AGT CTG T-30 and 50-TAA CAA TTG
TGG AAC TGC AGC AAT TAT T-30. One microliter of WGA
product was examined for the selected STR marker. The
procedures performed were based on the method described in
Fiorentino et al.11Real-time PCR with fluorescence resonance energy
transfer hybridizationFor mutation analysis, 1 mL of WGA product was used
for real-time PCR using a LightCycler 480 instrument
(Roche, Branchburg, NJ, USA). The primers, 50-GCA GAT
TTG CAT TCC AAT ATA-30 (sense) and 50-GCT TTA CAA
CTT GAG AAC CAT-30 (antisense), were used for the
detection of c.6709C>T mutation. One probe was labeled
with fluorescein at the 30 end (50-GAA TAC GGA TTA TCT
GCT TTA TCT GCC C-30) as the donor, and another probe
(acceptor) was labeled with the LightCycler red fluorophore
at the 50 end (50-TGA GAC ACT CAT TTG CTA ATA CAC
C-30). The procedures and conditions of real-time PCR and
melting curve analysis had been described previously in
details [12].Sequencing analysisPCR was performed in a total volume of 25 mL containing
1 mL of WGA products, 0.12 mM of each primer (50-GCTATT
ACT GTA TGA TCA ATG-30 and 50-TAT GCT TTA CAA
CTT GAG AAC-30), 100 mM dNTPs, 0.5 units of AmpliTaq
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USA), 2 mM MgCl2, and 2.5 mL of GeneAmp 10 buffer II
(10 mM Tris-HCl, pH ¼ 8.3, 50 mM KCl), as provided by the
manufacturer. Amplification was performed in a multiblock
system thermocycler (ThermoHybaid, Ashford, UK). PCR
amplification was performed with an initial denaturation step
at 95C for 10 minutes, followed by 35 cycles consisting of
denaturation at 94C for 30 seconds, annealing at 53C for 30
seconds, and extension at 72C for 30 seconds, and then a final
extension step at 72C for 10 minutes. Sequencing reactions
were separated on a PE Biosystems 373A/3100 sequencer (PE
Applied Biosystems).PGD using trophectoderm biopsyOvarian stimulation was performed with a long gonado-
tropin releasing hormone analog protocol as described previ-
ously [13]. Intracytoplasmic sperm injection was used to avoid
contamination from sperm and cumulus cells. Trophectoderm
biopsy was performed at the blastocyst stage, based on the
method described by Kokkali et al [6]. A specimen containing
approximately 5e10 trophoblast cells with clearly visible
nuclei was removed from each blastocyst. The specimen was
washed and transferred to a separate PCR tube. The last wash
drop of each specimen served as a blank control.Vitrification of blastocystsAfter biopsy, individual blastocyst was treated with cryo-
protectants and transferred onto the Cryotop (Kitazati Supply
Co., Fujinomiya, Japan) [14]. It was vitrified and stored in
liquid nitrogen separately.Thawed embryo transferIn the next cycle, using hormonal replacement treatment to
prepare endometrium [15], two unaffected blastocysts were
thawed and transferred. The pregnancy was followed by
prenatal examinations.Reanalysis of affected embryosThe affected embryos were thawed and reanalyzed to
confirm the results of genetic analysis.ResultsGenetic analysis using single lymphocytesBefore performing the PGD cycle, 50 single lymphocytes
of the wife were examined by MDA, genotyping using real-
time PCR, and STR detection. The amplification efficiency of
the NF-1 gene for a single lymphocyte was 94% (47/50) with
an ADO rate of 15% (7/47). There was no contamination in 50
reactions.Trophectoderm biopsy and vitrification of blastocystsIn the PGD cycle, 26 oocytes were retrieved that 21 were
mature and 16 were fertilized. Thirteen embryos developing to
blastocysts were biopsied. Individual blastocyst was then
vitrified in each Cryotop device.Molecular diagnosis of the samples of trophoblast cellsThe samples of trophoblast cells were processed by MDA,
genotyping using both real-time PCR and sequencing, and STR
detection. The results of real-time PCR (Fig. 1) revealed that
eight embryos were unaffected, four were affected, and one was
inconclusive diagnosis because of ADO. The data of
sequencing (Fig. 2) were same that confirmed the results of real-
time PCR. The amplification efficiency of theNF-1 gene for the
samples of trophoblast cells was 100% (13/13) with an ADO
rate of 8% (1/13). There was no contamination in 13 reactions.Transfer of thawed embryos and follow-up of pregnancyIn the next cycle, two unaffected blastocysts were thawed
and all of them survived. Two blastocysts were transferred.
The patient had a singleton pregnancy. The genotype of the
fetus was confirmed as unaffected by NF-1 using chorionic
villi sampling at 11 weeks’ gestation. Cesarean section was
performed at 26 weeks’ gestation because of severe
preeclampsia. A female baby was delivered, weighing 600 g
with Apgar scores of 6e8.Reanalysis of affected embryosThe four affected embryos were thawed and reanalyzed.
The data were same as the results of trophectoderm biopsy.
Discussion
We demonstrate the successful application of blastocyst
biopsy, vitrification, WGA with double confirmatory geno-
typings, and thawed embryo transfer for PGD of NF-1.
Embryo biopsy and fresh embryo transfer are conventionally
executed in the PGD cycle. However, before embryo transfer,
the time allowed for shipment and genetic analysis of the
specimens is restricted, particularly after blastocyst biopsy.
Cryopreservation of biopsied blastocysts instead of fresh
transfer permits sufficient time for accomplishment of
molecular diagnosis with double confirmations. And then
thawed embryo transfer is performed in the next cycle. In
addition, cryopreservation of embryos may be beneficial for
patients of high responder to circumvent risk of ovarian
hyperstimulation syndrome and possible suboptimal endome-
trium [16,17].
Compared with cleavage-stage biopsy, trophectoderm
biopsy providing more cells for genetic analysis may poten-
tially reduce the risk of amplification failure and ADO [6]. In
addition, trophectoderm biopsy would be relatively cost-
effective and less labor-intensive, because only embryos
Fig. 1. Melting curve analysis of real-time polymerase chain reaction with fluorescence resonance energy transfer hybridization for detection of the c.6709C>T
mutation of the NF1 gene. (A) Blue curve: husband; gray curve: wife; green curve: embryos. The peak at the lower melting temperature (60.5C) belonged to the
wild-type allele, whereas the peak at the higher melting temperature (66C) belonged to the mutated allele. The husband and an embryo with the wild-type
genotype revealed one melting peak (arrow) at 60.5C. (B) The wife and an embryo with the heterozygous c.6709C>T mutation showed one melting peak at
60.5C and an additional melting peak (arrow) at 66C.
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Kokkali et al [6] prospectively compared genotyping success
and implantation rates in PGD cycles for b-thalassemia after
biopsy at the blastocyst versus the cleavage stage. They found
that the genotyping success rate was significantly higher in the
blastocyst group (94%) than in the cleavage-stage group
(75%). The implantation and pregnancy rates were not
statistically different. With the higher genotyping success
rates, trophectoderm biopsy may result in relatively moreFig. 2. The sequencing analysis for detection of the c.6709C>T mutation of the NF1
(arrow). (B) Thewifewith the heterozygous c.6709C>Tmutation showed oneblue pe
revealed a single blue peak (arrow). (D) An embryo with the heterozygous c.6709C>embryos available for transfer. However, the case number is
still small in that series. In the present case of trophectoderm
biopsy for NF-1, the amplification rate was 100% with an
ADO rate of 8%. The value of blastocyst biopsy in reducing
ADO and achieving accurate diagnosis needs further
clarification.
The risk of ADO could lead to misdiagnosis in PGD.
Polymorphic STR markers close to mutated gene have been
used to provide an evidence of ADO [7,8]. MDA using Phi29gene. (A) The husband with the wild-type genotype revealed a single blue peak
ak and an additional red peak (arrow). (C)An embryowith thewild-typegenotype
T mutation showed one blue peak and an additional red peak (arrow).
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developed for WGA of scanty DNA material with unbiased
amplification [18]. In this study, we used MDA for WGA of
the sample of approximately 5e10 trophoblast cells. After
WGA, the NF1 gene and the selected STR marker can be
examined independently. We applied two genotyping methods
for double confirmations of diagnosis and obtained consistent
results. In addition, WGA allows reassuring examinations for
an ambiguous result. A few clinical applications of MDA for
PGD have been reported, such as for Marfan syndrome,
Duchenne muscular dystrophy, cystic fibrosis, b-thalassemia,
and Hungtington chorea [19]. Here we present the clinical
application of MDA for PGD of NF-1.
We first validate the successful application of blastocyst
biopsy, vitrification, WGA accompanied by double confirma-
tory genotypings and STR detection, and thawed embryo
transfer for PGD of NF-1. Cryopreservation of blastocysts
after biopsy permits more sufficient time for shipment of the
samples and performance of molecular diagnosis. Trophecto-
derm biopsy provides more cells for analysis that may reduce
amplification failure and ADO. After WGA, the quality and
quantity of DNA may facilitate multiple independent exami-
nations of gene mutations and polymorphic STR markers as
well as repeating confirmations for an uncertain result. Further
studies may merit to clarify an overall advantage of this
strategy regarding efficiency, diagnostic accuracy, and preg-
nancy potential.Acknowledgment
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